Overview
Testosterone Isocaproate is a testosterone ester used in hormone replacement and performance protocols. As a medium-length ester, it has a half-life of ~4 days (96 hours). It is tracked in Milligram with one-compartment pharmacokinetic modeling for accurate level predictions.
With a half-life of ~4 days (96 hours), Testosterone Isocaproate supports less frequent dosing schedules. Administered via IM injection, it has a bioavailability of approximately 95% via its primary route.
Half-life approximately 96 hours. Primarily found in the Sustanon 250 blend.
Mechanism of Action
Testosterone Isocaproate's pharmacological activity involves the following key pathways:
Androgen Receptor Binding
Testosterone Isocaproate binds to androgen receptors in skeletal muscle and other tissues, initiating transcription of androgen-responsive genes involved in protein synthesis and nitrogen retention.
Aromatization
Testosterone Isocaproate is subject to aromatase enzyme conversion, producing estrogenic metabolites. The rate of conversion varies with dose and individual enzyme activity.
Ester Hydrolysis
After injection, the ester bond is cleaved by esterase enzymes, releasing free testosterone into circulation. The ester length determines the rate of release and thus the half-life.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
100 mg/week
Route
Intramuscular
Frequency
2x per week
Duration
8-16 weeks
Dose
200 mg/week
Route
Intramuscular
Frequency
2x per week
Duration
8-16 weeks
Frequently Asked Questions
What is testosterone isocaproate?
Testosterone isocaproate is a medium–length testosterone ester with a half–life of approximately 84 hours (3.5 days). It is most widely known as one of four esters in Sustanon 250, where it contributes to the blend's sustained mid–range release phase. Standalone isocaproate formulations are uncommon, and most users encounter this ester exclusively through multi–ester blends.
How does testosterone isocaproate compare to enanthate and cypionate?
Testosterone isocaproate has a shorter half–life than enanthate (~168 hours) and cypionate (~192 hours), reaching steady state in approximately 17–18 days compared to 3–4 weeks for the longer esters. However, it is considerably longer–acting than phenylpropionate (36 hours) or propionate (20 hours). This positions isocaproate in a moderate–length tier, bridging short and long esters within blends like Sustanon 250.
How long does testosterone isocaproate take to reach steady state?
With a half–life of approximately 84 hours, steady–state concentrations are generally reached after 17–18 days of consistent dosing (5 × 84h / 24h ≈ 17.5 days). This is faster than enanthate or cypionate, though users of Sustanon 250 often experience earlier subjective effects from the shorter propionate and phenylpropionate components in the blend.
What injection frequency is appropriate for testosterone isocaproate?
Standalone isocaproate is most commonly observed administered twice weekly or every 3–4 days, given its approximately 84–hour half–life. More frequent injections (EOD) would keep levels highly stable but are not required. Less frequent administration — such as once weekly — would produce wider peak–to–trough swings than longer–ester options on the same schedule.
Is testosterone isocaproate available as a standalone compound?
Standalone testosterone isocaproate is rarely available through commercial channels. It is primarily encountered as part of the Sustanon 250 blend (along with propionate, phenylpropionate, and decanoate). Some specialty compounding pharmacies may formulate it as a single–ester product, but demand and availability remain limited compared to enanthate, cypionate, or propionate.
What are the side effects of testosterone isocaproate?
Testosterone isocaproate shares the androgenic and estrogenic side effect profile common to all testosterone esters. Commonly observed effects include acne, water retention, increased libido, and suppression of endogenous testosterone production. Because it is most often used within multi–ester blends, isolating effects specific to the isocaproate ester is generally not practical. Side effect intensity is primarily dose–dependent regardless of ester selection.